Description Results NMA

vildagliptin (50 mg given once or twice daily) (n=515)

vs.

placebo (n=0)

double-blind

Sample size: 515/0

Primary endpoint:

FU duration: 24 weeks

vildagliptin (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (100 mg daily, given as 50 mg twice daily (n=441)

vs.

acarbose (up to 300 mg daily, given as three equally divided doses (n=220)

double-blind

Sample size: 441/220

Primary endpoint:

FU duration: 24 weeks

Vildagliptin 50 mg Bid (n=-9)

vs.

Voglibose 0.2 mg Tid (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

vildagliptin (50 mg bid, (n=188)

vs.

voglibose (0.2 mg tid (n=192)

double-blind

Sample size: 188/192

Primary endpoint:

FU duration: 12 weeks

Adverse events leading to treatment discontinuation 1.01 [0.33; 3.07]

Adverse events leading to treatment discontinuation 4.38 [1.29; 14.86]

Adverse events leading to treatment discontinuation ∞ [NaN; ∞]

Adverse events leading to treatment discontinuation 0.60 [0.10; 3.47]

Adverse events leading to treatment discontinuation 2.24 [0.89; 5.68]

Adverse events leading to treatment discontinuation NaN [NaN; NaN]

Adverse events leading to treatment discontinuation 1.73 [0.52; 5.81]

Adverse events leading to treatment discontinuation 9.50 [1.22; 74.05]

Adverse events leading to treatment discontinuation 1.25 [0.34; 4.57]

all hypoglycemia ∞ [NaN; ∞]

vildagliptin 50 mg or 100 mg daily (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin 20 mg or 50 mg or 100 mg daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin 50 mg or 100 mg daily, imag (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin 25mg bid (n=70)

vs.

placebo (n=28)

double-blind

Sample size: 70/28

Primary endpoint:

FU duration:

vildagliptin 25mg or 50mg or 100mg daily (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin 50 mg qd (n=156)

vs.

placebo (n=150)

double-blind

Parallel groups

Sample size: 156/150

Primary endpoint:

FU duration: 52 weeks

vildagliptin 50 mg daily (add-on to metformin therapy)j (n=56)

vs.

placebo (add-on to metformin therapy)mag (n=51)

double-blind

Sample size: 56/51

Primary endpoint:

FU duration: 12 weeks

vildagliptin (50 or) 100 mg daily (add-on to metformin therapy)m (n=185)

vs.

placebo (add-on to metformin therapy)mag (n=182)

double-blind

Sample size: 185/182

Primary endpoint:

FU duration:

vildagliptin 100 mg daily (add-on to insulin therapy)y) (n=144)

vs.

placebo (add-on to insulin therapy)y)mag (n=152)

double-blind

Sample size: 144/152

Primary endpoint:

FU duration: 24 weeks

vildagliptin 50 or 100 mg daily (add-on to pioglitazone therapy) (n=463)

vs.

placebo (add-on to pioglitazone therapy) (n=0)

Sample size: 463/0

Primary endpoint:

FU duration:

ildagliptin 100 mg given in the morning, vildagliptin 100 mg given in the evening (n=125)

vs.

placebo (n=122)

double-blind

Parallel groups

Sample size: 125/122

Primary endpoint:

FU duration: 24 weeks

vildagliptin (50 mg q.d.) (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

vildagliptin plus high-dose metformin combination therapy (50 mg + 1000 mg twice daily), (n=1179)

vs.

high-dose metformin monotherapy (1000 mg twice daily). (n=0)

Sample size: 1179/0

Primary endpoint:

FU duration: 24 weeks

vildagliptin 100 mg (n=29)

vs.

placebo (n=30)

Sample size: 29/30

Primary endpoint:

FU duration:

vildagliptin 50mg bid (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Vildagliptin and Metformin (25/1000 mg Bid) (n=-9)

vs.

Metformin Monotherapy (1000 mg Bid) (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin 50mg twice-daily (n=102)

vs.

placebo (n=100)

double-blind

Sample size: 102/100

Primary endpoint:

FU duration: 12 weeks

Vildagliptin 50 mg Bid or qd (n=-9)

vs.

placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin 50mg qd, 50mg bid or 100mg qd (n=-9)

vs.

placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 12 weeks

Vildagliptin 100 mg o.d. (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (100 mg/d) (n=-9)

vs.

placebo (n=-9)

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (n=-9)

vs.

placebo (n=-9)

Cross over

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (50 mg qd) (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin added to insulin (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

all hypoglycemia 0.10 [0.07; 0.16]

HbA1c goal <7% 0.97 [0.90; 1.05]

vildagliptin 50 mg twice daily (n=1396)

vs.

glimepiride titrated up to 6 mg/day (n=1393)

double-blind

Parallel groups

Sample size: 1396/1393

Primary endpoint: HbA1c

FU duration: 52 weeks

vildagliptin (50 mg twice daily (n=513)

vs.

gliclazide (up to 320 mg/day (n=494)

double-blind

Sample size: 513/494

Primary endpoint:

FU duration: 52 weeks

monotherapy with vildagliptin 50 mg bid (n=-9)

vs.

gliclazide up to 320 mg/day (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 2 years

vildagliptin (n=-9)

vs.

glimepiride (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 2 years

Adverse events leading to treatment discontinuation 0.58 [0.30; 1.10]

vildagliptin 100mg (n=526)

vs.

metformin up to 2000 mg daily (n=254)

Sample size: 526/254

Primary endpoint:

FU duration: 52 weeks

vildagliptin (100 mg daily) (n=-9)

vs.

metformin (2 000 mg daily). (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin (100 mg daily (n=169)

vs.

metformin (titrated to 1500 mg daily (n=166)

Sample size: 169/166

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Adverse events leading to treatment discontinuation 0.95 [0.38; 2.36]

Adverse events leading to treatment discontinuation 0.47 [0.15; 1.49]

vildagliptin 100 mg daily daily (n=519)

vs.

rosiglitazone 8 mg once daily (n=267)

double-blind

Sample size: 519/267

Primary endpoint:

FU duration: 24 weeks

vildagliptin 100 mg daily daily (n=-9)

vs.

pioglitazone 30 mg dailyaily (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

vildagliptin 100 mg daily (add-on to metformin therapy) (n=295)

vs.

pioglitazone 30 mg daily (add-on to metformin therapy)j (n=281)

double-blind

Sample size: 295/281

Primary endpoint:

FU duration:

vildagliptin 50 mg or 100 mg daily plus 15 mg or 30 mg pioglitazone dailyi (n=-9)

vs.

pioglitazone 30 mg daily (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: 24 weeks

vildagliptin 100 mg (n=1653)

vs.

TZD (agent and dose at the investigators' discretion (n=825)

Sample size: 1653/825

Primary endpoint:

FU duration:

vildagliptin (50 mg b.i.d (n=396)

vs.

rosiglitazone (8 mg q.d., (n=202)

double-blind

Sample size: 396/202

Primary endpoint:

FU duration: